BioNTech | 6-K: Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer
BioNTech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
BioNTech | 6-K: BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
BioNTech | 6-K: BioNTech to Present Clinical Data Updates For Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024
BioNTech | 6-K: BioNTech Announces Planned Retirement of Sean Marett
BioNTech | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
BioNTech | 6-K: BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
BioNTech | 6-K: Biontech and Dualitybio Receive Fda Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305
BioNTech | 6-K: BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Metastatic Breast Cancer
BioNTech | 6-K: BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial Cancer
BioNTech | 6-K: BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda
BioNTech | 6-K: BioNTech and Australia’s State of Victoria Sign Agreement on Strategic Partnership to Strengthen mRNA Ecosystem
BioNTech | 6-K: Innovation Series Day 2023 Presentation
BioNTech | 6-K: Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19
BioNTech | 6-K: BioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advanced Solid Tumors at ESMO Congress 2023
BioNTech | 6-K: BioNTech to Present Multiple Program Updates Across Modalities at ESMO Congress 2023
BioNTech | 6-K: Update Regarding Pfizer’s Statement on COMIRNATY-Related Write-Offs
BioNTech | 6-K: Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine
BioNTech | 6-K: Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union
BioNTech | 6-K: BioNTech Expands Management Board by Appointing James Ryan as Chief Legal Officer
No Data